BIOCORP, a French company specialized in the development and manufacturing of medical devices and smart drug delivery systems, announces today the signature of a partnership agreement with Théa, the European leader in the field of ophthalmology.
Under this agreement, BIOCORP and Laboratoires Théa (through Thea Open Innovation) are joining forces to design, develop and manufacture connected medical devices to help patients suffering from blinding diseases such as glaucoma. The device developed makes it possible to participate in the therapeutic education of patients and to improve their quality of life as well as that of healthcare professionals.
Jean-Frédéric Chibret, President of Théa, said: “We are very pleased to be able to rely on BIOCORP’s expertise in the development of connected medical devices within different therapeutic areas in order to develop, in the near future, a new ecosystem for patients. We see technological innovation as a lever, which must be used to strengthen the doctor-patient bond. This agreement is the culmination of several years of working together to define the contours of a health approach connected to the ophthalmology department. THEA Laboratories have always been committed to patients and health professionals. They offer increasingly innovative technologies to improve the quality of life of patients.”
Eric Dessertenne, Chief Executive Officer of BIOCORP, added: “We have been collaborating in confidence with Thea Laboratories for many years. We are very proud of this new partnership because it allows us to deploy BIOCORP’s two areas of expertise: the production of innovative and secure products for the pharmaceutical industry and the design of a connected environment dedicated to patient compliance. This agreement with Théa represents a very interesting industrial opportunity and marks our entry into the ophthalmology market and its associated services.”
